Exogene is a biotechnology company accelerating the discovery of T-cell-receptor (TCR)- based cancer immunotherapies for solid tumours by combining deep learning and high-throughput TCR-antigen screening. Their mission is to develop better TCR-based cancer immunotherapies, faster and at a fraction of the cost.
Focus: Drug discovery platform
Spaces are limited to 10 companies per cohort. Contact Marco to get more information on our next programme in spring 2024.Contact Marco